Company news

Jointown Pharmaceutical Group Co., Ltd. Class A (SSE:600998) news

Jointown Pharmaceutical Group Co., Ltd. Class A news releases on 6ix. Latest, Sep 29, 2026: "Jointown Pharmaceutical Group Co., Ltd."Announcement on Release…

Jointown Pharmaceutical Group Co., Ltd. Class A (SSE:600998) news

Press releases & updates

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Release of Pledge and Pledge of Shares by the Controlling Shareholder and Its Person Acting in Concert

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Progress in Providing Guarantees for Subsidiaries

"Jointown Pharmaceutical Group Co., Ltd."Indicative Announcement on Convening the 3rd Extraordinary General Meeting in 2026

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Outline of the 2026 Semi-annual Performance Briefing

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 24th Meeting of the 6th Board of Directors

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Winning of a Bid by a Controlled Subsidiary for the County-level Medical Community Information Integration Construction Project

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Issuance of the Second Tranche of Asset-backed Commercial Paper for 2026 (Supporting the Elderly Care Industry) and Related Party Transactions

"Jointown Pharmaceutical Group Co., Ltd."Semi-annual Report for 2026

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Signing of the "Strategic Cooperation Agreement" with Guomin Pension & Insurance Co., Ltd. and Related Party Transactions

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 22nd Meeting of the 6th Board of Directors

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Provision of Online Voting Reminder Service for General Meeting

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Acquisition of the Compliance Management System Certification Certificate

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Election of Directors, Appointment of Senior Management and Resignation of Directors

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Early Release of Pledge and Pledge of Shares by the Controlling Shareholder and Its Persons Acting in Concert

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Completion of Redemption of the First Tranche of Sci-Tech Innovation Bonds in 2026

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Inclusion of Products of Subsidiaries in the "National Essential Medicines List (2026 Edition)"

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Progress in Providing Guarantee for Subsidiary

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Entrusted Wealth Management of Temporarily Idle Funds for Q2 2026

"Jointown Pharmaceutical Group Co., Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction

Announcement on Resolutions of the 20th Meeting of the 6th Board of Directors

Announcement on Release and Pledge of Shares by the Controlling Shareholder and Its Persons Acting in Concert

Announcement on Progress in Providing Guarantee for Subsidiary

Announcement on Issuance of the Phase I Asset-backed Notes for 2026 and Related Party Transactions

Announcement on Subsidiary Obtaining Approval for Marketing of Chemical APIs

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation

Announcement on Resolutions of the 2025 Annual General Meeting

Indicative Announcement on Convening the 2025 Annual General Meeting

Announcement on Recognition of Subsidiary as High-tech Enterprise

Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs

Announcement on Holding Subsidiary Certified as High-tech Enterprise

Report for Q1 2026

Announcement on Results of Issuing Phase II Ultra-Short-Term Financing Bonds of 2026

Announcement on the Subsidiary Receiving the "Acceptance Notice" from the National Medical Products Administration for the Market Application of Azelastine Hydrochloride Nasal Spray

Announcement on Temporary Idle Funds’ Investment Management Arrangements for Q1 2026

Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors

Announcement on Obtaining Medical Device Registration Certificate by Holding Subsidiary

Announcement on the Results of Issuance of the 2026 Phase II Science and Technology Innovation Bonds

Announcement on Advance Release and Pledge of Shares by the Controlling Shareholder and Its Persons Acting in Concert

Announcement on the Subsidiary Receiving the "Acceptance Notice" from the National Medical Products Administration for the Market Application of Betahistine Hydrochloride Tablets

Announcement on Completion of Industrial and Commercial Change Registration and Filing of Articles of Association

Announcement on the Results of Issuance of the 2026 Phase I Science and Technology Innovation Bonds

Announcement on Entrusted Financial Management in Q4 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Obtaining Drug Registration Certificate for Bupivacaine Hydrochloride Injection

Announcement on Provision of Online Voting Reminder Service for General Meeting

Announcement on Early Release of Pledge and Pledge of Shareholders' Shares

Announcement on Completion of Execution of Reorganization Plan of Aoyuan Beauty Valley Technology Co., Ltd., in Which the Wholly-owned Subsidiary Participated as a Reorganization Investor

Announcement on Obtaining Drug Registration Certificate for Isopropylamine Hydrochloride Injection